SynopsisMetformin, marketed under the trade name Glucophage among others, is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. The global Metformin Hydrochloride Tablet market was valued at US$ 3784 millio.....
SynopsisGlucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have .....
SynopsisTeduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome. The global Glucagon-like Peptide-2 (GLP-2) Agonist market w.....
SynopsisTeduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome. The global Teduglutide market was valued at US$ 751 million.....
SynopsisTeduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome. The global Teduglutide Drugs market was valued at US$ 751 m.....
SynopsisGlatiramer is an immunomodulator medication currently used to treat multiple sclerosis. The global Glatiramer market was valued at US$ 1072 million in 2023 and is anticipated to reach US$ 597.1 million by 2030, witnessing a CAGR of -6.8% during the forec.....
SynopsisGlatiramer is an immunomodulator medication currently used to treat multiple sclerosis. The global Glatiramer Drugs market was valued at US$ 1072 million in 2023 and is anticipated to reach US$ 597.1 million by 2030, witnessing a CAGR of -6.8% during the.....
SynopsisGlatiramer acetate is an immunomodulator medication currently used to treat multiple sclerosis. The global Glatiramer Acetate market was valued at US$ 1072 million in 2023 and is anticipated to reach US$ 597.1 million by 2030, witnessing a CAGR of -6.8% .....
SynopsisExenatide is a medication used to treat diabetes mellitus type 2. The global Exenatide Drugs market was valued at US$ 284 million in 2023 and is anticipated to reach US$ 167.8 million by 2030, witnessing a CAGR of -6.8% during the forecast period 2024-20.....
SynopsisSomatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormone.....
